FIRM

Main information

  • Trade name:
  • FIRM 6 XL CHEWING GUM
  • Pharmaceutical form:
  • XL CHEWING GUM
  • Composition:
  • 6
  • Medicine domain:
  • Humans
  • Medicine type:
  • Allopathic drug

Documents

Localization

  • Available in:
  • FIRM 6 XL CHEWING GUM
    India
  • Language:
  • English

Other information

Status

  • Source:
  • Central Drugs Standard Control Organization
  • Last update:
  • 09-08-2016

19-4-2018

April 13, 2018: Canadian Drug Firm Admits Selling Counterfeit and Misbranded Prescription Drugs Throughout the United States

April 13, 2018: Canadian Drug Firm Admits Selling Counterfeit and Misbranded Prescription Drugs Throughout the United States

April 13, 2018: Canadian Drug Firm Admits Selling Counterfeit and Misbranded Prescription Drugs Throughout the United States

FDA - U.S. Food and Drug Administration

30-11-2017

Nutra Labs Inc. Issues Voluntary Nationwide Recall of Dietary Supplements Bull and Chao Jimengnan Tablets Due to Undeclared Active Pharmaceutical Ingredients

Nutra Labs Inc. Issues Voluntary Nationwide Recall of Dietary Supplements Bull and Chao Jimengnan Tablets Due to Undeclared Active Pharmaceutical Ingredients

Nutra Labs Inc. is voluntarily recalling lots sold by their firm of the male enhancement supplements Bull 1800 mg Capsules with the production date of 05/08/2016, and Chao Jimengnan 150 mg Tablets with Lot # 20151018 to the consumer level. FDA analysis found the products to be tainted with sildenafil, 0.026mg/capsule for Bull, and 70.46mg/tablet for Chao Jimengnan respectively. Sildenafil is the active pharmaceutical ingredient in an FDA approved product used for erectile dysfunction, making Bull capsule...

FDA - U.S. Food and Drug Administration

29-6-2017

FDA unveils plan to eliminate orphan designation backlog

FDA unveils plan to eliminate orphan designation backlog

Today, the U.S. Food and Drug Administration unveiled a strategic plan to eliminate the agency’s existing orphan designation request backlog and ensure continued timely response to all new requests for designation with firm deadlines. The agency’s Orphan Drug Modernization Plan comes a week after FDA Commissioner Scott Gottlieb committed to eliminating the backlog within 90 days and responding to all new requests for designation within 90 days of receipt during his testimony before a Senate subcommittee.

FDA - U.S. Food and Drug Administration

14-6-2017

Phillips Company Issues Voluntary Worldwide Recall of All Topical Products Due to Concerns of Manufacturing Practices

Phillips Company Issues Voluntary Worldwide Recall of All Topical Products Due to Concerns of Manufacturing Practices

Phillips Company is voluntarily recalling all lots of Tetrastem, Diabecline, Tetracycline-ABC, VenomX, Acneen, StaphWash, StringMed, NoPain and LidoMed distributed by Phillips Company, with business offices located in Sun City, Arizona, to the retail level. The products are being recalled after an FDA inspection found significant manufacturing practices that calls into question the safety, identity, strength, quality and purity of unexpired drug products made at the firm during the past three years.

FDA - U.S. Food and Drug Administration

17-10-2017

#SafeSleep tip #2: Use a firm sleep surface, such as a mattress in a safety-approved crib. Learn more:  http://bit.ly/2dRt4Wc  #SIDSpic.twitter.com/AGSy9kF5Qq

#SafeSleep tip #2: Use a firm sleep surface, such as a mattress in a safety-approved crib. Learn more: http://bit.ly/2dRt4Wc  #SIDSpic.twitter.com/AGSy9kF5Qq

#SafeSleep tip #2: Use a firm sleep surface, such as a mattress in a safety-approved crib. Learn more: http://bit.ly/2dRt4Wc  #SIDS pic.twitter.com/AGSy9kF5Qq

FDA - U.S. Food and Drug Administration